Using rib cartilage to treat ankle joint lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of using autologous costal osteochondral transplantation to treat Hepple Stage V talar osteochondral lesions. Participants will be randomly assigned to receive either the experimental treatment or a control treatment involving autologous osteoperiosteal transplantation. The study aims to determine if the rib cartilage method leads to better clinical outcomes and less donor site morbidity compared to the control. All participants will follow the same rehabilitation and follow-up protocols post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points;
* Failed conservative treatment for at least 6 months;
* Unilateral talar osteochondral lesions without corresponding lesions on the tibial side;
* Willingness to participate in this clinical trial and signing an informed consent form.

Exclusion Criteria:

* Combined with lower limb deformity.
* Combined with hip or knee joint diseases.
* Combined with ipsilateral ankle arthritis with joint space narrowing .
* Diagnosis of gouty arthritis of the ankle joint.
* Combined with osteoporosis (T score \<-2.5).
* Other conditions considered inappropriate for participation in this clinical trial by the researchers.

Where it's running

• The Third Affiliated Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Canjun Zeng, PhD — The Third Affiliated Hospital of Southern Medical University
• Study coordinator: Hao Guo, MD
• Email: 416363977@qq.com
• Phone: +8617612003968

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MACI versus bone marrow stimulation for symptomatic ankle cartilage defects in people 17–65

  This treatment comparison tests whether MACI (your own cultured cartilage cells on a collagen membrane) works better than bone marrow stimulation for people aged 17 to 65 with symptomatic cartilage defects of the talus.

  Recruiting at 12 sites Phase 3 Vericel Corporation · Gilbert, Arizona and 11 other locations · NCT06915233

• Comparing AMIC and microfracture for hip cartilage damage

  This study is testing whether a new treatment called AMIC works better than microfracture for helping people with hip cartilage damage feel better and improve their quality of life after surgery.

  Recruiting Phase 1 McMaster University · Hamilton, Ontario · NCT05402072

• Evaluating CartiLife® for knee cartilage defects

  This study is testing if a new treatment using patients' own cartilage cells can help adults with knee cartilage damage feel better and improve their knee function.

  Recruiting at 4 sites Phase 2 Biosolution Co., Ltd. · Irvine, California and 4 other locations · NCT04744402

• Using autologous chondrocyte suspension for knee cartilage repair

  This study is testing whether using a patient’s own cartilage cells can help repair knee cartilage damage and improve their knee function over a year.

  Recruiting Centre Hospitalier Universitaire Vaudois · Lausanne, Canton of Vaud · NCT04296487

• Comparing MACI and microfracture treatments for knee cartilage defects in teens

  This study is testing whether a new cartilage treatment called MACI works better than a standard procedure called microfracture for knee problems in teens aged 10 to 17.

  Recruiting at 12 sites Phase 3 Vericel Corporation · Palo Alto, California and 14 other locations · NCT03588975

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.